EGFR and colorectal carcinoma: Following the identification of two anti-epidermal growth factor receptor (EGFR)-targeted antibodies, cetuximab (Erbitux) and panitumumab (Vectibix), the treatment of CRC has stepped into the world of personalized therapies.